# A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

Source: https://onco.cc/trials/nct07465835/  
OnCo record `nct07465835` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Ipsoprubart run by Electra Therapeutics Inc., now recruiting.

## Summary

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs) is a phase 1 interventional study registered as NCT07465835 by Electra Therapeutics Inc., with 84 participants planned, started 2026-02-17, primary completion expected 2028-06. Conditions recorded: T Cell Malignancies. Interventions recorded: ELA026.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07465835
- Phase: 1
- Setting: A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
- Sponsor: Electra Therapeutics Inc.
- Enrolled: 84

## Sources

- ClinicalTrials.gov NCT07465835: https://clinicaltrials.gov/study/NCT07465835

## Connected records

- drugs: [Ipsoprubart](https://onco.cc/drugs/ipsoprubart/)
- companies: [Electra Therapeutics](https://onco.cc/companies/electra-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07465835.json